Investment Banking Institution-Laidlaw & Company

Relmada Therapeutics, we have to serve as a company that is involved in the development as well as manufacture of clinical-stage drugs that are mainly used for the purpose of chronic illness treatment. Recently our management team made an announcement that was purposely meant to make amendments of the complaints we had previously made. The motion that our organization filed was against Laidlaw& Company for the breach of fiduciary duty as well as the disclosure of confidential information that it owned our firm when it was acting as our investment bank.
Our management team learned that the Nevada Court had previously issued an injunction associated as well as a temporary restraining order to the Laidlaw & Company management team that included Mathew Eitner and James Ahern.  Our management team wishes to be compensated by Laidlaw for the costs it made us suffer and also the investment firm must be prevented from harming to our organization in the future.
Laidlaw &Company (UK Ltd) is one of the leading investment companies that has been operating in the United States as well as the United Kingdom. The firm can be described as a fully serviced as well as a brokerage firm that has a primary mandate of providing personalized advice as well as skillful execution to both private and institutions and high-net-worth individuals’ investors. Laidlaw offers a broad range of services and products that include acquisition financing, initial public offering, placement of debt, placement of equity, mezzanine capital with institution investors, and the arrangement of national exchange listing. Mathew Eitner is the Chief Executive Officer while his co-leader James Ahern serves as the Partner and Head of Capital Markets.